S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)

Nevro (NVRO) Stock Price, News & Analysis

$14.41
-0.01 (-0.07%)
(As of 09:37 AM ET)
Today's Range
$14.34
$14.49
50-Day Range
$13.56
$19.01
52-Week Range
$13.36
$39.67
Volume
5,002 shs
Average Volume
483,440 shs
Market Capitalization
$524.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.23

Nevro MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
61.1% Upside
$23.23 Price Target
Short Interest
Bearish
12.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.53) to ($2.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.25 out of 5 stars

Medical Sector

772nd out of 939 stocks

Surgical & Medical Instruments Industry

82nd out of 99 stocks

NVRO stock logo

About Nevro Stock (NYSE:NVRO)

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company's Senza HFX iQ IPG system includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, it offers surpass surgical and percutaneous leads. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

NVRO Stock Price History

NVRO Stock News Headlines

my top trade on these 9 tickers
This indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.
NVRO Mar 2024 20.000 put
Nevro just downgraded at Oppenheimer, here's why
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Why Nevro Stock Lagged the Market on Thursday
Hold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 Outlook
Analyst Scoreboard: 4 Ratings For Nevro
Nevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call Transcript
Nevro: Q4 Earnings Snapshot
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
NVRO Mar 2024 22.500 call
Nevro Corp
Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update
See More Headlines
Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/28/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Fax
N/A
Employees
1,215
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.23
High Stock Price Target
$40.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+61.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
13 Analysts

Profitability

Net Income
$-92,210,000.00
Pretax Margin
-23.02%

Debt

Sales & Book Value

Annual Sales
$425.17 million
Book Value
$8.10 per share

Miscellaneous

Free Float
35,306,000
Market Cap
$524.89 million
Optionable
Optionable
Beta
0.91
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Roderick H. MacLeod (Age 57)
    Senior VP & CFO
    Comp: $729.61k
  • Mr. Kashif RashidMr. Kashif Rashid (Age 50)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $703.35k
  • Mr. Kevin R. Thornal (Age 50)
    President, CEO & Director
  • Mr. Richard B. Carter (Age 53)
    Chief Accounting Officer
  • Mr. Christofer Christoforou (Age 54)
    Senior Vice President of Technical Operations
    Comp: $367.4k
  • Geeta Kaveti
    VP and Chief Compliance & Privacy Officer
  • Mr. Jon R. Shear
    Senior Vice President of Corporate Development
  • Meredith Vornholt
    Vice President of Global Marketing
  • Ms. Shana D. Ross M.B.A.
    Senior VP & Chief of Human Resources Officer
  • Dr. David Caraway M.D. (Age 67)
    Ph.D., Senior VP & Chief Medical Officer

NVRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Nevro stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 1 sell rating, 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings
or view top-rated stocks.

What is Nevro's stock price target for 2024?

13 Wall Street analysts have issued 1-year target prices for Nevro's stock. Their NVRO share price targets range from $15.00 to $40.00. On average, they predict the company's share price to reach $23.23 in the next year. This suggests a possible upside of 61.1% from the stock's current price.
View analysts price targets for NVRO
or view top-rated stocks among Wall Street analysts.

How have NVRO shares performed in 2024?

Nevro's stock was trading at $21.52 at the start of the year. Since then, NVRO stock has decreased by 33.0% and is now trading at $14.42.
View the best growth stocks for 2024 here
.

When is Nevro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our NVRO earnings forecast
.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) announced its quarterly earnings data on Wednesday, February, 21st. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.35. The medical equipment provider had revenue of $116.18 million for the quarter, compared to analyst estimates of $115.93 million. Nevro had a negative net margin of 21.69% and a negative trailing twelve-month return on equity of 30.22%.

What ETFs hold Nevro's stock?
What guidance has Nevro issued on next quarter's earnings?

Nevro updated its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $97.0 million-$99.0 million, compared to the consensus revenue estimate of $98.7 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Who are Nevro's major shareholders?

Nevro's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.23%), Vanguard Group Inc. (11.17%), Armistice Capital LLC (8.77%), Braidwell LP (4.91%), Goldman Sachs Group Inc. (2.89%) and Goldman Sachs Group Inc. (2.88%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane and Shawn Mccormick.
View institutional ownership trends
.

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NVRO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners